Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.39 |
| ▸ | KLK1 | P06870 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 2/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232469 | 0.84 | PARP1 (0.57) | PARP1CNR2PCSK9KLKB1KLK1 | |
| SCHEMBL3465649 | 0.81 | PARP1 (0.57) | PARP1CNR2PCSK9KLKB1KLK1 | |
| SCHEMBL5172659 | 0.81 | PARP1 (0.57) | PARP1CNR2PCSK9KLKB1KLK1 | |
| SCHEMBL17229320 | 0.80 | ALDH1A1 (0.41) | PARP1PANK3SMN1; SMN2 | |
| SCHEMBL19501403 | 0.78 | CNR2 (0.49) | PARP1CNR2PCSK9FGFR3HRH3 | |
| SCHEMBL14408313 | 0.78 | PARP1 (0.54) | PARP1CNR2PCSK9KLKB1KLK1 | |
| SCHEMBL17897210 | 0.78 | ACACB (0.55) | ACACB | |
| SCHEMBL17229262 | 0.77 | IDH1 (0.39) | IDH1PANK3 | |
| SCHEMBL469807 | 0.76 | CNR2 (0.52) | PARP1CNR2PCSK9FGFR3HRH3 | |
| SCHEMBL14367676 | 0.76 | AOC3 (0.47) | CNR2HRH3PANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| WO-2015171527-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | PARP1 1782/4885CNR2 3014/4885PCSK9 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.